Amiko receives CE mark for use of the Respiro Platform with Teva’s Spiromax®, Chiesi's Nexthaler® and GlaxoSmithKline's Ellipta® inhalers

    Press/Media: Expert Comment › Popular

    Period5-Feb-2018

    Media contributions

    1

    Media contributions

    • TitleAmiko receives CE mark for use of the Respiro Platform with Teva’s Spiromax®, Chiesi's Nexthaler® and GlaxoSmithKline's Ellipta® inhalers
      Degree of recognitionInternational
      Media typeWeb
      Country/TerritoryNetherlands
      Date05/02/2018
      URLwww.prweb.com/releases/2018/02/prweb15164006.htm
      PersonsJob van Boven
    View all 1
    View less